文献速递乳腺癌

CPS+EG评分在三阴性乳腺癌新辅助化疗中的效用

Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
PubMed 文献 · Eur J Cancer · 2021-06-26

该研究基于8项德国前瞻性试验的1795例三阴性乳腺癌患者,评估CPS+EG评分在新辅助化疗后的预后价值。结果显示CPS+EG评分预后信息优于临床分期但劣于病理分期,且无法区分两个最佳预后组(评分1和2)。pCR状态在CPS+EG评分之上提供额外预后信息,pCR仍是最强且最有临床用的预后因素。

要点

  • CPS+EG评分预后信息优于临床分期但劣于病理分期。
  • CPS+EG评分无法区分评分1和2两个最佳预后组。
  • pCR在CPS+EG评分之上提供额外预后信息。

核心结论

  • 在三阴性乳腺癌中,CPS+EG评分预后信息劣于病理分期,无法识别无pCR且预后足够好可避免新辅助后治疗的患者。
  • pCR仍是新辅助化疗后最强且最有临床用的预后因素。
  • 三阴性乳腺癌需要pCR之外的其它生物学因素。

研究设计与样本

  • 研究纳入8项德国前瞻性试验的1795例三阴性乳腺癌患者,计算CPS+EG评分。
  • 采用Kaplan-Meier法计算5年无病生存(DFS)和总生存估计。

主要发现

  • pCR患者(ypT0/is ypN0,n=822,45.8%)5年DFS为86%。
  • 残留AJCC I期疾病患者(n=383,21.3%)5年DFS为77.5%。
  • CPS+EG评分预后信息优于临床分期但劣于病理分期(c-index统计,p<0.001)。
  • CPS+EG评分无法区分评分1和2两个最佳预后组(n=362,37.2%)。
  • CPS+EG评分3分患者总体5年DFS为64%,其中pCR者5年DFS为84%,无pCR者仅49.7%。

临床怎么用

  • 在三阴性乳腺癌新辅助化疗后,pCR状态应作为主要预后评估依据。
  • CPS+EG评分不宜单独用于筛选可避免新辅助后治疗的无pCR患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is associated with superior survival. This association is strongest in triple-negative breast cancer (TNBC). The CPS + EG system, based on pre-treatment clinical (CS) and post-treatment pathological stage (PS), oestrogen-receptor status (E) and grade (G), leads to a refined estimate of prognosis after NACT in all-comers and hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here, we investigate if CPS + EG scoring provides a superior estimate of prognosis in TNBC to select patients for postneoadjuvant therapy. METHODS: We calculated the CPS + EG score for 1795 patients with TNBC from 8 prospective German trials. Five-year disease-free survival (DFS) and overall survival estimates were calculated using the Kaplan-Meier method. RESULTS: In TNBC, patients with pCR (ypT0/is ypN0, n = 822, 45.8%) had a 5-year DFS of 86%, whereas patients with residual American Joint Committee on Cancer stage I disease (n = 383; 21.3%) had a 5-year DFS of 77.5%.CPS + EG led to superior prognostic information compared with that provided by the clinical stage, but it was inferior to the prognostic information provided by the pathological stage (c-index statistics, p < 0.001). CPS + EG did not discriminate prognosis within the two best prognostic groups (score 1 and 2; n = 362; 37.2%). In contrast, pCR status added prognostic information beyond CPS + EG. Patients with a CPS + EG score of 3 had a 5-year DFS rate of 64% overall, but those with pCR had a 5-year DFS rate of 84%, and those without pCR had a 5-year DFS rate of only 49.7%. CONCLUSIONS: In TNBC, CPS + EG scoring provided inferior prognostic information compared with the pathological stage and was unable to identify patients without pCR and with a sufficiently good prognosis, who could avoid postneoadjuvant therapy. pCR remains the strongest and most clinically useful prognostic factor after NACT. Other biologic factors beyond pCR are needed in TNBC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Marmé F, Solbach C, Michel L, et al. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2021. PMID: 34186505. doi:10.1016/j.ejca.2021.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。